Regencell Bioscience Holdings Limited RGC
6.17
0.00
0.00%
as of 25 Sep
- Market cap
- $3.1B
- P/E
- 0.0×
Follow RGC
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '23 | Jun '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+7 more quarters Free account |
19.15 | 41.91 | 7.38 | 1.42 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.09) | (0.02) | (1.97) | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | — | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(4.99) | (4.01) | (3.27) | (2.59) | |
Working Capital |
11.01 | 7.92 | 4.24 | 0.69 | |
Capital Expenditures |
(0.03) | (0.01) | (0.15) | — | |
Net Current Asset Value |
10.99 | 7.89 | 4.01 | 0.56 | |
| Other line items | |||||
Quick Ratio |
19.05 | 41.12 | 7.38 | 1.42 | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Average Assets |
6.48 | 14.75 | 11.89 | 9.28 | |
Average Common Equity |
4.00 | 13.96 | 10.97 | 7.95 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates